Sanara MedTech, Inc. (SMTI)

Sanara MedTech's stock price has significantly declined over the past year. In Q3 2025, the company reported earnings that exceeded expectations, but shares declined following the release. Sanara MedTech announced a strategic realignment, discontinuing the Tissue Health Plus (THP) segment to focus on its core surgical business. In Q2 2025, the company reported a 25.8% increase, with contributions from soft tissue and bone repair products. Sanara MedTech launched a pilot program through its subsidiary Tissue Health Plus (THP) for value-based wound care services. In Q1 2025, Sanara MedTech reported 26% year-over-year growth in net revenue for its surgical team and outlined plans to expand its distributor network.

Specific demand seasonality information for Sanara MedTech Inc.'s products is not readily available. However, the company operates in the medical technology sector, which generally experiences consistent demand driven by ongoing healthcare needs rather than strong seasonal fluctuations.

Sanara MedTech, Inc. is a medical technology company focused on developing, marketing, and distributing surgical, wound, and skincare products and services within the Healthcare sector. The company aims to improve clinical outcomes and reduce healthcare expenditures. Key products include CellerateRX Surgical Activated Collagen for wound management, BIASURGE Advanced Surgical Solution for wound irrigation, FORTIFY TRG Tissue Repair Graft, FORTIFY FLOWABLE Extracellular Matrix, TEXAGEN Amniotic Membrane Allograft, a portfolio of advanced biologic products for the surgical market including ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, and BiFORM Bioactive Moldable Matrix, and BIAKOS Antimicrobial Wound Gel and BIAKOS Antimicrobial Skin and Wound Cleanser. The company also has a pipeline of product candidates for mitigating opportunistic pathogens and biofilm, wound re-epithelialization and closure, necrotic tissue debridement, and cell-compatible substrates.

Sanara MedTech Inc. is based in Fort Worth, Texas, and primarily markets and distributes its products to physicians, hospitals, clinics, and post-acute care settings across the United States. Its products are mainly sold in the North American advanced wound care and surgical tissue repair markets.

Sanara MedTech aims to improve patient outcomes through technology and innovation, emphasizing integrity, collaboration, and a commitment to excellence. Its strategic advantages include a focus on developing, marketing, and distributing wound and skin care products to improve patient outcomes and reduce healthcare costs. The decision to discontinue the Tissue Health Plus (THP) segment indicates a strategic misstep, but the company's surgical segment continues to show solid growth and profitability.

The ownership structure of Sanara MedTech includes institutional, insider, and retail investors. Institutional investors hold approximately 1.53% to 8.10% of the stock, insiders hold 41.76%, and retail investors hold 50.33%. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Stonebridge Wealth Management, LLC. Ronald Nixon owns the most shares of Sanara MedTech.